DR-299 MutSig – The incidence and co-ocurrence of genomic biomarkers in metastatic tumors
The observed incidence of cancer biomarkers can influence resource investment into key areas such as drug discovery and companion diagnostic technology. The list of clinically relevant cancer biomarkers is growing, however a systematic description of the incidence of these biomarkers is currently lacking. Understanding the prevalence of these biomarkers in late-stage cancer can be especially relevant since many companion diagnostics are utilized in the treatment of stage III and IV cancers.
By using multiple publicly available knowledge management resources that describe clinically relevant alterations, we aim to characterize the frequency of these biomarkers and contextualize their associations within the Hartwig dataset.
Eivind Hovig, University of Oslo, Norge
Back to newsMore news
First time linking Hartwig Medical Database with the Netherlands Cancer Registry for AYA Patients
This July, the first data transfer was completed between the Netherlands Cancer Registry (NKR) and the Hartwig Medical Database for …
Collaboration for future-proof diagnostics and to accelerate research
Complete analysis of the DNA of children with cancer offers many possibilities. It maps out all possible targeted treatment options …
Hartwig advances precision oncology worldwide with oncoanalyser
Nicole Schonrock on scaling precision care for patients with cancer in Australia Hartwig Medical Foundation has developed powerful software for …
It is important to unravel the DNA in rare types of cancer; 21% of patients with cancer have a rare form.